Alopexx Vaccine
100 Main Street
Suite 110
Concord
Massachusetts
01742
United States
Website: http://www.alopexx.com/
About Alopexx Vaccine
Alopexx Vaccine, LLC is developing a vaccine against a proprietary antigenic target - dPNAG.
YEAR FOUNDED: 2006
LEADERSHIP:
Founders: Daniel R. Vlock, Deborah Ramsdell and Christine de los Reyes
Founder and CEO: Daniel R. Vlock
CLINICAL TRIAL:
4 articles about Alopexx Vaccine
-
Alopexx Vaccine Announces Licensing Agreement with Merck Animal Health
1/14/2019
Alopexx Vaccine, LLC announced today that it has entered into an exclusive global license agreement with Merck Animal Health to develop and commercialize its poly-N-acetyl glucosamine (PNAG) vaccine for Rhodococcus equi (R. equi) pneumonia in foals, as well as other infections in the equine field
-
Alopexx Vaccine Reports Successful Maternal Immunization Protecting Foals from an Intracellular Equine Pathogen Similar to Tuberculosis
7/19/2018
Immunization of Pregnant Horse Mares with PNAG-induced Antibody Vaccine Demonstrated Greater than 90% Protective Efficacy in 4-week-old Foals following Challenge with Live Rhodococcus. equi, a Common Equine Intracellular Pathogen closely related to M. tuberculosis
-
Alopexx Pharmaceuticals' F598 Monoclonal Antibody Binds to poly-N-acetylglucosamine (PNAG) on Microbial Surfaces Offering Potential Protective Immunity Against Multiple Pathogens
4/6/2018
Structure featured on the cover of the April 6 issue of the Journal of Biological Chemistry
-
Alopexx Completes First-in-Man Trial of its Novel, Broad-Spectrum Anti-Microbial Vaccine
10/25/2017
Alopexx today announced that it has completed a Phase I clinical trial with AV0328, a vaccine targeting the broadly expressed microbial antigen, poly-N-acetyl glucosamine.